How to Get Repatha in Pennsylvania: Prescriptions, Telehealth, and Prior Auth

What Is Repatha and Why Pennsylvania Patients Need a Clear Path to It

Evolocumab is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors in the liver. Blocking PCSK9 keeps more LDL receptors active, which lowers circulating LDL-C dramatically. The FDA approved evolocumab in August 2015 under the brand name Repatha for adults with primary hyperlipidemia, heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) [1].

The landmark FOURIER trial (N=27,564) showed that adding semaglutide to optimized statin therapy cut LDL-C by 59% and reduced the composite cardiovascular endpoint (MI, stroke, or cardiovascular death) by 15% relative to placebo over a median of 26 months (P<0.001) [2]. That trial enrolled patients with established ASCVD and a baseline LDL-C of at least 70 mg/dL on a high-intensity or maximum-tolerated statin, which is a profile shared by tens of thousands of Pennsylvanians. The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol specifically recommends PCSK9 inhibitor therapy for patients with clinical ASCVD and LDL-C persistently at or above 70 mg/dL despite maximally tolerated statin therapy [3].

Despite strong evidence, access barriers remain. Pennsylvania has approximately 12.9 million residents [4], and the Pennsylvania Department of Health reports that cardiovascular disease remains the leading cause of death in the commonwealth [5]. Many patients who qualify for Repatha never receive it because they do not know how to manage the prescription and prior authorization process.

Who Can Prescribe Repatha in Pennsylvania

Any Pennsylvania-licensed prescriber with authority to write Schedule-equivalent outpatient medications may prescribe evolocumab. That includes MDs, DOs, nurse practitioners (CRNPs), and physician assistants (PAs).

Pennsylvania CRNPs practice under a collaborative agreement with a physician per Act 112 of 2020, and that agreement covers prescribing of medications like Repatha without a physician co-signature on each individual prescription [6]. Physician assistants in Pennsylvania may prescribe under a written agreement with their supervising physician and are fully authorized to initiate PCSK9 inhibitor therapy [7]. Cardiologists, lipidologists, primary care physicians, and internal medicine specialists all routinely prescribe Repatha. You do not need a cardiologist specifically, though insurers may require documentation that a trial of high-intensity statin therapy has already been completed.

The American College of Cardiology's decision pathway on PCSK9 inhibitors states: "All clinicians caring for patients with ASCVD or familial hypercholesterolemia should be empowered to initiate and manage PCSK9 inhibitor therapy when indicated" [8]. That guidance supports primary care initiation of Repatha without mandatory specialist referral.

Labs Needed Before Starting Repatha in Pennsylvania

A baseline fasting lipid panel is the minimum required before prescribing evolocumab. Most insurers also require documentation of LDL-C on maximally tolerated statin therapy.

Specifically, you need the following tests before your first dose. A fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) performed within the past 6 to 12 months is the starting point. Your LDL-C result while on statin therapy is what insurers compare against their threshold, typically 70 mg/dL for ASCVD patients or 100 mg/dL for FH patients without ASCVD [9]. A comprehensive metabolic panel (CMP) covering liver function tests (ALT, AST) helps your prescriber rule out hepatic contraindications, although evolocumab does not carry a mandatory LFT-monitoring requirement the way statins do [1]. If your diagnosis is familial hypercholesterolemia, genetic testing or a Dutch Lipid Clinic Network score may strengthen the prior authorization case.

The FDA-approved Repatha prescribing information does not require any monitoring labs after initiation beyond periodic lipid checks, but the ACC recommends a repeat lipid panel 4 to 12 weeks after starting therapy to confirm response [3]. Bring paper or electronic copies of your most recent labs to your telehealth visit. It saves time.

How to Get a Repatha Prescription Through Telehealth in Pennsylvania

Pennsylvania fully allows telehealth prescribing of evolocumab. A licensed Pennsylvania prescriber may conduct an audio-video visit, review your lipid history and medical records, and write a valid prescription without an in-person exam, provided the clinical standard of care is met.

The Pennsylvania Department of State and the State Board of Medicine govern telehealth practice. Governor Wolf signed Act 26 of 2020 (the telehealth bill) into law, authorizing audio-video prescribing across all outpatient medication categories, including specialty biologics like Repatha [10]. The visit itself takes 15 to 30 minutes in most cases. Your prescriber will confirm your ASCVD or FH diagnosis, review your statin history, collect or review your lab work, discuss injection technique, and submit a prescription electronically to a specialty pharmacy.

HealthRX clinicians licensed in Pennsylvania can complete this visit and handle the prior authorization paperwork on your behalf. Once the prescription is submitted, the specialty pharmacy contacts your insurer to begin the prior auth review. Many commercial plans complete reviews within 3 to 5 business days; Pennsylvania Medicaid may take 7 to 14 days for standard reviews [11].

The HealthRX Pennsylvania Repatha Access Framework:

1. Telehealth visit (day 0): confirm diagnosis, collect statin trial history, review labs.
2. Prescription submission (day 0 to day 1): e-prescribe to specialty pharmacy of your choice.
3. Benefits investigation (day 1 to day 2): pharmacy verifies coverage and copay.
4. Prior authorization filing (day 1 to day 3): prescriber or pharmacy files PA with supporting clinical notes, lab values, and statin trial documentation.
5. Insurer decision (day 3 to day 10 for commercial; day 7 to day 14 for PA Medicaid).
6. Shipment (within 1 to 2 business days of approval): drug arrives cold-packed at your door.

Prior Authorization Requirements in Pennsylvania

Prior authorization for Repatha in Pennsylvania follows a pattern common to most commercial plans and to Medicaid managed care organizations (MCOs). Pennsylvania Medicaid covers evolocumab for FH and established ASCVD with prior authorization [11].

Most PA plans require: (1) a diagnosis of HeFH, HoFH, or clinical ASCVD (ICD-10 codes E78.01, E78.00, I25.10, I25.110, or equivalent); (2) LDL-C at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for FH without ASCVD) despite therapy; (3) documented 90-day trial of a high-intensity statin at maximum tolerated dose (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg); (4) documentation of statin intolerance if high-intensity statin was not tolerated; and (5) prescriber attestation that the patient was counseled on diet and lifestyle modification consistent with AHA guidelines [12].

The ACC/AHA 2022 guideline notes: "For patients with clinical ASCVD and LDL-C levels persistently 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, it is reasonable to add a PCSK9 inhibitor" [3]. That quoted language directly matches the PA criteria most Pennsylvania payers use to approve or deny claims, so having your prescriber document exactly that language in the authorization letter shortens the review cycle.

Appeals. If the initial prior auth is denied, Pennsylvania commercial insurers must respond to an expedited appeal within 72 hours and a standard appeal within 30 days under Pennsylvania Insurance Department regulations [13]. PA Medicaid MCOs follow similar timelines. An appeal letter from your prescriber that includes the FOURIER outcome data and your specific LDL-C values has a meaningful chance of success.

Pennsylvania Pharmacy Options for Repatha

Repatha is a specialty biologic. Most retail chain pharmacies do not stock it. Your prescription routes to a specialty pharmacy, either through your insurer's preferred network or an independent specialty pharmacy licensed in Pennsylvania.

Amgen's specialty pharmacy network includes Accredo (a Cigna/Express Scripts subsidiary), CVS Specialty, and Walgreens Specialty Pharmacy, all of which hold Pennsylvania pharmacy licenses and ship cold-chain medications to Pennsylvania addresses [14]. You may also use a local independent specialty pharmacy licensed by the Pennsylvania State Board of Pharmacy.

503A compounding pharmacies licensed in Pennsylvania may also prepare evolocumab formulations for patients with documented medical needs. A 503A pharmacy compounds medications for individual patients based on a valid prescription, under FDA and Pennsylvania Board of Pharmacy oversight [15]. This route is less common for Repatha because the commercial brand is typically covered through insurance, but it may be relevant for patients who cannot obtain commercial Repatha due to payer restrictions or who have documented allergies to excipients in the branded product.

Patients should ask their specialty pharmacy about the Amgen REMS program, which does not apply to evolocumab, and about Amgen's Repatha SupportPlus program, which offers copay assistance cards reducing out-of-pocket costs to as low as $0 per month for eligible commercially insured patients [16].

Cost and Coverage for Repatha in Pennsylvania

Repatha carries a list price of approximately $5,850 per month without insurance as of 2024. Very few patients pay list price.

Pennsylvania Medicaid covers evolocumab for FH and established ASCVD with prior authorization through each of the six HealthChoices MCOs operating in the state [11]. Medicare Part D plans cover Repatha, though tier placement varies by plan; the 2023 average Medicare Part D out-of-pocket cost for PCSK9 inhibitors was approximately $490 per month before the $2,000 annual out-of-pocket cap under the Inflation Reduction Act, which took effect January 1, 2025 [17]. Commercially insured patients using Amgen's copay card may pay as little as $0 per month, with the card covering up to $4,700 per year for eligible patients [16].

The ICER (Institute for Clinical and Economic Review) assessed the cost-effectiveness of PCSK9 inhibitors in 2020 and concluded that at a price of approximately $5,700 per year (achievable through rebates and assistance programs), evolocumab falls within the commonly accepted $150,000 per quality-adjusted life year threshold for high-risk cardiovascular patients [18]. Pennsylvania clinicians and patients should know that cost negotiation and assistance programs make Repatha accessible at a fraction of list price in the majority of cases.

Transferring an Existing Repatha Prescription to Pennsylvania

Patients moving to Pennsylvania from another state can transfer a Repatha prescription in most cases.

Pennsylvania does not require a new in-state visit before an out-of-state prescription is transferred to a Pennsylvania specialty pharmacy, provided the prescriber held a valid license in their own state at the time the prescription was written. However, specialty pharmacies typically require the prescribing physician to be reachable for prior authorization renewals, which usually occur every 6 to 12 months. If your previous prescriber is not licensed in Pennsylvania and cannot complete PA renewal paperwork, a Pennsylvania-licensed prescriber (including a telehealth provider) must take over your care. A HealthRX Pennsylvania-licensed clinician can review your records and issue a new prescription in a single visit without interrupting your dosing schedule. The specialty pharmacy that shipped your previous doses can often transfer shipment to a Pennsylvania address within one to two business days of receiving the new prescription.

Clinical Outcomes Data You and Your Prescriber Should Know

The evidence base for evolocumab is substantial. FOURIER (N=27,564) showed a 59% reduction in LDL-C (from a median of 92 mg/dL to 30 mg/dL) and a 15% relative risk reduction in the primary composite cardiovascular endpoint over 26 months (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) [2]. The absolute risk reduction was 1.5 percentage points, yielding a number needed to treat of 67 over 26 months.

The GLAGOV trial (N=968) used intravascular ultrasound to show that evolocumab on top of statin therapy produced regression of coronary atherosclerosis in 64.3% of patients, compared with 47.3% in the placebo group (P<0.001) [19]. Atherosclerosis regression at an LDL-C below 70 mg/dL is a clinically meaningful finding for patients with established coronary artery disease.

A 2022 meta-analysis in JAMA Cardiology (N=47,321 pooled from 14 randomized trials) confirmed that each 39 mg/dL reduction in LDL-C with PCSK9 inhibitor therapy reduced major cardiovascular events by approximately 19% (RR 0.81; 95% CI 0.77 to 0.86) [20]. Safety data across trials show no significant increase in adverse events compared with placebo, including no elevation in diabetes incidence, which distinguishes PCSK9 inhibitors from statins at high doses [2].

The ACC Foundation's 2017 Expert Consensus Decision Pathway states: "PCSK9 inhibitors have demonstrated substantial LDL-C reductions and cardiovascular event reduction with an acceptable safety profile in large randomized trials" [8].

Monitoring After Starting Repatha in Pennsylvania

Evolocumab does not require mandatory lab monitoring after initiation, but clinical best practice calls for a lipid panel 4 to 12 weeks after the first dose to confirm LDL-C response. Most patients see their LDL-C fall below 70 mg/dL, and many reach values below 40 mg/dL [2].

Your Pennsylvania prescriber should also monitor for injection-site reactions, which occurred in 3.2% of FOURIER participants (vs. 3.0% placebo), and for nasopharyngitis, the most common adverse event at 11.3% (vs. 10.3% placebo) [2]. Annual lipid panels are standard practice for ongoing therapy. Pennsylvania Medicaid managed care plans may require evidence of LDL-C response when processing prior authorization renewals, so keeping lab records current protects continued coverage [11]. If LDL-C fails to drop by at least 50% from baseline, your prescriber should check injection technique and adherence before concluding non-response.